Clinical Takeaway
In this small pilot trial of 20 adults with diagnosed insomnia disorder, a single oral dose of 10 mg THC combined with 200 mg CBD reduced total sleep time compared to placebo, suggesting that at least in the short term, this cannabinoid combination did not improve objective sleep duration. Patients and clinicians should be cautious about assuming that cannabis products automatically improve sleep, as the physiological reality measured by EEG may differ substantially from subjective perception of sleep quality.
#8 Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.
Citation: Suraev Anastasia et al.. Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.. Journal of sleep research. 2026. PMID: 40631525.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This pilot study provides the first high-resolution neurophysiological characterization of how a standardized THC/CBD formulation affects sleep architecture in patients with diagnosed insomnia disorder, addressing a critical gap between widespread clinical use and limited objective evidence regarding efficacy and safety. The use of high-density EEG enables detection of subtle changes in sleep stage composition and cortical activity that standard polysomnography cannot resolve, potentially clarifying mechanisms by which cannabinoids influence sleep while revealing whether next-day cognitive or alertness deficits occur. These findings are essential for establishing evidence-based dosing and patient selection criteria for cannabinoid-based sleep interventions in clinical practice.
Methodological Considerations:
- Self-reported outcomes — recall and social-desirability bias risk
Abstract: Cannabinoids, particularly Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), have gained popularity as alternative sleep aids; however, their effects on sleep architecture and next-day function remain poorly understood. Here, in a pilot trial, we examined the effects of a single oral dose containing 10 mg THC and 200 mg CBD (THC/CBD) on objective sleep outcomes and next-day alertness using 256-channel high-density EEG in 20 patients with DSM-5 diagnosed insomnia disorder (16 female; mean (SD) age, 46.1 (8.6) years). We showed that THC/CBD decreased total sleep time (-24.5 min, p = 0.05, d = -0.5) with no change in wake after sleep onset (+10.7 min, p > 0.05) compared to placebo. THC/CBD also significantly decreased time spent in REM sleep (-33.9 min, p < 0.001, d = -1.5) and increased latency to REM sleep (+65.6 min, p = 0.008, d = 0.7). High-density EEG analysis revealed regional decreases in gamma activity during N2 sleep, and in delta activity during N3 sleep, and a regional increase in beta and alpha activity during REM sleep. While there was no observed change in next-day objective alertness, a small but significant increase in self-reported sleepiness was noted with THC/CBD (+0.42 points, p = 0.02, d = 0.22). No changes in subjective sleep quality, cognitive performance, or simulated driving performance were observed. These findings suggest that a single dose of cannabinoids, particularly THC, may acutely influence sleep, primarily by suppressing REM sleep, without noticeable next-day impairment (≥ 9 h post-treatment). Australian New Zealand Clinical Trial Registry (ACTRN12619000714189) https://www.anzctr.org.au/.
😴 This pilot study offers valuable objective EEG data on acute cannabinoid effects in insomnia, but several limitations warrant caution before clinical application. The small sample size of 20 patients, female predominance, and single-dose design limit generalizability and prevent assessment of tolerance or efficacy with repeated dosing, which is how patients actually use these agents. The specific THC/CBD ratio tested (10:200 mg) may not reflect the ratios or dosing patterns most patients employ, and we lack critical information on next-day cognitive and psychomotor effects that could impact safety. Despite these constraints, this work addresses a genuine evidence gap by moving beyond subjective sleep reports to quantifiable neurophysiologic measures, which clinicians need when counseling insomnia patients considering cannabinoids. Until larger, longer trials establish safety and efficacy trajectories, practitioners should view cannabinoids as a potential option for selected insomniac patients only after discussing realistic expectations, the immaturity of the evidence base, and the need